CG Oncology, Inc.

CGON

CG Oncology, Inc.

CGON

Insider Sentiment (TTM):

Last Purchase:2026-06-25Last Sale:2026-06-24Shares Purchased (TTM):1,886,236Shares Sold (TTM):199,920

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:75,463,619Shares Outstanding:84,518,512Institutional Ownership Pct.:89.29%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	20	34	32	45	15	41	257	43	25	77
Marketable Securities Current	1,009	1,043	710	635	646	647	485	497	528	489
Inventory Net	1	1	2	2	-	-	0	-	-	-
Receivables Net Current	0	1	1	1	-	-	0	-	-	-
Prepaid Expense And Other Assets Current	20	23	15	14	11	12	12	11	11	12
Assets Current	1,050	1,102	759	696	673	701	754	552	564	579
Property Plant And Equipment Net	15	15	16	15	0	0	0	0	0	0
Operating Lease Right Of Use Asset	6	5	4	4	1	1	0	0	0	0
Finite Lived Intangible Assets Net	1	1	1	2	-	-	0	-	-	-
Deferred Costs	-	-	-	-	-	-	0	-	-	-
Goodwill	10	10	10	13	10	-	0	-	-	-
Accounts And Other Receivables Net Current	-	-	-	-	1	0	1	0	0	0
Other Assets Noncurrent	5	3	2	0	1	1	0	0	0	0
Assets	1,086	1,135	792	730	701	728	755	552	564	579
Liabilities And Stockhold…
Notes And Loans Receivable Net Noncurrent	-	-	-	-	27	25	-	-	-	-
Liabilities Current
Accounts Payable Current	13	8	6	9	7	7	7	4	4	5
Operating Lease Liability Current	1	1	1	1	0	0	0	0	0	0
Accrued Liabilities And Other Liabilities	34	26	24	20	23	16	15	11	7	5
Liabilities Current	47	35	31	31	30	23	21	16	12	10
Long Term Debt Noncurrent	3	3	3	3	-	-	0	-	-	-
Operating Lease Liability Noncurrent	5	4	3	3	1	1	0	0	0	0
Business Combination Recognized Identifiable Asset…	0	0	0	2	-	-	0	-	-	-
Other Liabilities Noncurrent	1	1	2	4	-	-	0	-	-	-
Liabilities	57	43	39	42	31	23	21	16	12	10
Temporary Equity
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,547	1,531	1,132	1,025	964	957	951	723	718	716
Series A1 Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Retained Earnings Accumulated Deficit	-518	-439	-379	-338	-294	-252	-218	-186	-166	-147
Stockholders Equity	1,029	1,092	753	688	670	705	733	537	552	569
Series B Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Liabilities And Stockholders Equity	1,086	1,135	792	730	701	728	755	552	564	579
Series C Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Series D Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Series E Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Series F Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	700	700	700	700	700	700	700	700	700	700
Common Stock Shares Issued	88	88	81	78	76	76	76	68	67	67
Shares Outstanding	88	88	81	78	76	76	76	68	67	67

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.53%	3.36%	-0.43%	-	-	-	-	-	-	-	-	-
2025	11.29%	11.25%	8.81%	7.93%	51.07%	75.73%	5.58%	1.90%	26.92%	10.68%	24.88%	13.83%
2024	8.53%	5.16%	10.16%	10.95%	13.93%	9.45%	-6.46%	-17.47%	-18.69%	-21.88%	-3.75%	-2.12%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Liquidity Ratios
Current Ratio	22.22	31.30	24.63	22.79	22.15	30.97	35.30	35.32	47.57	57.95
Quick Ratio	21.78	30.60	24.09	22.30	21.78	30.42	34.72	34.60	46.66	56.76
Working Capital	1.00B	1.07B	728.64M	665.26M	642.65M	678.55M	732.84M	536.45M	552.01M	568.63M
Leverage & Debt
Debt to Equity	0.05	0.04	0.05	0.06	0.05	0.03	0.03	0.03	0.02	0.02
Debt Ratio	0.05	0.04	0.05	0.06	0.04	0.03	0.03	0.03	0.02	0.02
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.01	0.00	0.00	0.00	0.00	-	-	-
Days Sales Outstanding TTM	24.44	91.77	62.16	86.47	-	-	-	-	-	-
Receivables Turnover TTM	14.94	3.98	5.87	4.22	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.54	-2.21	-2.08	-1.97	-1.68	-1.39	-1.41	-	-	-
Free Cash Flow Per Share TTM	-1.72	-1.90	-1.71	-1.14	-0.85	-1.08	-1.26	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Operating Profit Margin TTM	-4,056.18%	-4,238.99%	-4,722.13%	-8,285.33%	-28,546.10%	-20,302.27%	-10,067.25%	-	-	-
Net Profit Margin TTM	-3,602.68%	-3,682.61%	-3,985.02%	-6,968.08%	-23,245.55%	-15,945.47%	-7,729.50%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	1,030.31%	666.01%	254.70%	-	-	-	-	-	-	-
Net Income Growth (1Y)	75.18%	76.91%	82.87%	-	-	-	-	-	-	-
EPS Growth (1Y)	51.40%	59.47%	47.84%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-27.93	-30.63	-19.94	-20.40	-15.47	-17.68	-20.36	-	-	-
P/B TTM	6.09	5.24	4.26	4.49	2.96	2.65	2.44	4.72	3.81	3.63
P/S TTM	1,006.20	1,128.02	794.47	1,421.65	3,596.91	2,818.48	1,573.67	-	-	-
Market Cap	6.27B	5.72B	3.21B	3.09B	1.98B	1.87B	1.79B	2.53B	2.10B	2.07B
Enterprise Value	6.25B	5.69B	3.18B	3.05B	1.97B	1.82B	1.68B	2.49B	2.08B	1.99B
Calculated Values
Free Cash Flow TTM	-151.39M	-160.44M	-132.48M	-87.84M	-64.77M	-82.22M	-78.95M	-	-	-
Net Debt	-16.64M	-30.70M	-29.49M	-42.15M	-14.62M	-41.47M	-111.03M	-43.41M	-25.16M	-77.47M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-25Purchase

Owner: Liu, Brian Guan-Chyun

Title: -

Shares: 371,085

Price/Share: $66.87

Value: $24,814,453.95

Shares Owned: 1,886,236

Relationship: Director

Ownership: Indirect

2026-06-24Sale

Owner: Post, Leonard E

Title: -

Shares: 5,000

Price/Share: $70.00

Value: $350,000.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-06-22Sale

Owner: Post, Leonard E

Title: -

Shares: 5,000

Price/Share: $65.00

Value: $325,000.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-06-15Sale

Owner: Mulay, James

Title: -

Shares: 1,964

Price/Share: $60.12

Value: $118,075.68

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Post, Leonard E

Title: -

Shares: 1,000

Price/Share: $54.50

Value: $54,500.00

Shares Owned: -

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-25	Liu, Brian Guan-Chyun	Director	-	Indirect	Purchase	371,085	66.87	$24,814,453.95	1,886,236	4
2026-06-24	Post, Leonard E	Director	-	Direct	Sale	5,000	70.00	$350,000.00	0	4
2026-06-22	Post, Leonard E	Director	-	Direct	Sale	5,000	65.00	$325,000.00	0	4
2026-06-15	Mulay, James	Director	-	Direct	Sale	1,964	60.12	$118,075.68	0	4
2026-06-04	Post, Leonard E	Director	-	Direct	Sale	1,000	54.50	$54,500.00	0	4
2026-04-17	Mulay, James	Director	-	Direct	Sale	15,600	73.01	$1,138,956.00	0	4
2026-03-16	Mulay, James	Director	-	Direct	Sale	1,964	63.50	$124,714.00	0	4
2026-01-09	Mulay, James	Director	-	Direct	Sale	11,145	48.58	$541,424.10	0	4
2025-11-17	Post, Leonard E	Director	-	Direct	Sale	1,000	41.43	$41,430.00	0	4
2025-10-13	Post, Leonard E	Director	-	Direct	Sale	1,000	43.25	$43,250.00	0	4
2025-10-09	Mulay, James	Director	-	Direct	Sale	5,903	43.99	$259,672.97	0	4
2025-09-30	Post, Leonard E	Director	-	Direct	Sale	5,000	40.09	$200,450.00	0	4
2025-09-29	Mulay, James	Director	-	Direct	Sale	12,755	39.19	$499,868.45	0	4
2025-09-19	Mulay, James	Director	-	Direct	Sale	3,574	38.99	$139,350.26	0	4
2025-09-15	Post, Leonard E	Director	-	Direct	Sale	1,000	35.10	$35,100.00	0	4
2025-09-11	Liu, Brian Guan-Chyun	Director	-	Indirect	Purchase	1,515,151	33.00	$49,999,983.00	1,515,151	4
2025-09-05	Mulay, James	Director	-	Direct	Sale	27,015	31.94	$862,859.10	0	4
2025-09-03	Song, Hong Fang	Director	-	Indirect	Sale	100,000	28.45	$2,845,000.00	2,903,931	4
2025-09-03	Post, Leonard E	Director	-	Direct	Sale	1,000	28.00	$28,000.00	0	4
2025-07-17	Post, Leonard E	Director	-	Direct	Sale	2,000	28.00	$56,000.00	0	4
2025-05-21	Post, Leonard E	Director	-	Direct	Sale	1,000	28.00	$28,000.00	0	4
2025-04-28	Post, Leonard E	Director	-	Direct	Sale	1,000	30.76	$30,760.00	0	4
2025-03-17	Post, Leonard E	Director	-	Direct	Sale	1,000	28.00	$28,000.00	0	4
2025-02-18	Post, Leonard E	Director	-	Direct	Sale	1,000	28.61	$28,610.00	0	4
2025-01-13	Post, Leonard E	Director	-	Direct	Sale	1,000	29.66	$29,660.00	0	4
2024-12-16	Song, Hong Fang	Director	-	Indirect	Sale	700,000	28.00	$19,600,000.00	3,003,931	4
2024-12-16	Post, Leonard E	Director	-	Direct	Sale	1,000	28.84	$28,840.00	0	4
2024-12-06	Post, Leonard E	Director	-	Direct	Sale	1,000	34.69	$34,690.00	0	4
2024-08-29	Song, Hong Fang	Director	-	Indirect	Sale	650,455	35.36	$23,000,088.80	586,982	4
2024-01-29	Decheng, Capital Global H…	TenPercentOwner	-	Indirect	Purchase	400,000	19.00	$7,600,000.00	400,000	4
2024-01-29	Roche, Corleen M.	Officer	CFO & Secretary	Direct	Purchase	2,000	19.00	$38,000.00	2,000	4
2024-01-29	Decheng, Capital Global H…	TenPercentOwner	-	Direct	Purchase	400,000	19.00	$7,600,000.00	4,958,810	4/A
2024-01-29	Song, Hong Fang	Director	-	Direct	Purchase	263,157	19.00	$4,999,983.00	613,928	4
2024-01-29	Kasturi, Vijay	Officer	Chief Medical Officer	Direct	Purchase	1,315	19.00	$24,985.00	1,315	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

89.29%

Inst. Shares: 75,463,619

Shares Outstanding: 84,518,512

2025-12-31

101.51%

Inst. Shares: 78,470,645

Shares Outstanding: 77,303,440

2025-09-30

98.97%

Inst. Shares: 75,936,592

Shares Outstanding: 76,729,726

2025-06-30

96.33%

Inst. Shares: 73,430,728

Shares Outstanding: 76,226,829

2025-03-31

91.29%

Inst. Shares: 69,549,350

Shares Outstanding: 76,187,621

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	75,463,619	84,518,512	89.29%
2025-12-31	78,470,645	77,303,440	101.51%
2025-09-30	75,936,592	76,729,726	98.97%
2025-06-30	73,430,728	76,226,829	96.33%
2025-03-31	69,549,350	76,187,621	91.29%
2024-12-31	65,077,215	62,496,725	104.13%
2024-09-30	51,395,662	67,143,744	76.55%
2024-06-30	42,506,571	66,649,443	63.78%
2024-03-31	35,404,202	47,064,768	75.22%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CG Oncology, Inc. (CGON) — SEC Financial Statements & Analysis

CG Oncology, Inc. (CGON) is a biological products, (no diagnostic substances) company, incorporated in DE. CG Oncology, Inc. trades on Nasdaq as: CGON. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CG Oncology, Inc. reported a 1030.31% year-over-year revenue growth, a Debt-to-Equity ratio of 0.05x, a Price-to-Sales (P/S) ratio of 1006.20x (TTM), a Price-to-Book (P/B) ratio of 6.09x (TTM), at a market cap of $6.27B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 1030.31%
Debt To Equity: 0.05x
P/S TTM: 1006.20x
P/B TTM: 6.09x
Market Cap: $6.27B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CG Oncology, Inc. in?

CG Oncology, Inc. (CGON) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CGON's market cap?

CG Oncology, Inc. (CGON) has a market capitalization of $6.27B as of 2026-06-30.

What exchange does CGON trade on?

CG Oncology, Inc. (CGON) trades on the Nasdaq.

Where is CG Oncology, Inc. incorporated?

CG Oncology, Inc. is incorporated in DE.

CG Oncology, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

CG Oncology, Inc. (CGON) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

CG Oncology, Inc. (CGON) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.